Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged 6 months~* Finished two doses of vaccination (0,1 month) of hepatitis B vaccine prior to study entry~* Proven legal identity~* Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study~Exclusion Criteria:~* Finished all the three doses vaccination (0,1,6 month) of hepatitis B vaccine prior to study entry~* Prior vaccination of meningococcal polysaccharide vaccine~* Prior vaccination of EV71 vaccine~* Unable to receive vaccination on both arms~* History of hand foot and mouth disease~* Previously tested HBsAg positive~* Mother of the subject had been previously tested HBsAg positive~* History of asthma; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc~* Congenital malformation, developmental disorders, genetic defects~* Autoimmune disease or immunodeficiency/immunosuppressive~* Severe nervous system disease or mental illness~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders~* Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry~* Receipt of blood product (e.g., immunoglobulin) within 3 months prior to study entry~* Receipt of any other investigational medicine(s) within 30 days prior to study entry~* Receipt of any live attenuated vaccine within 14 days prior to study entry~* Receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry~* Acute disease or acute stage of chronic disease within 7 days prior to study entry~* Axillary temperature \> 37.0 ℃~* Any other factor that suggesting the volunteer is unsuitable for this study based on the judgement of investigators~Exclusion Criteria of the Second Injection:~* Subjects with one of the following 1 to 3 conditions are forbidden to continue vaccination, while the other study steps could be carried out based on the judgement of investigator; for subjects with one of the following 4 to 5 conditions, whether to continue vaccination are determined by the investigator; for subjects with one of the following 6 to 7 conditions, vaccination may be delayed in the time window specified in the study:~  1. Any serious adverse event that has a causal relationship with the investigated vaccine (except the group II)~ 2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination, except the group II )~ 3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)~ 4. New chronic diseases or acute stage of chronic diseases~ 5. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions) determined by the investigators~ 6. Acute diseases (moderate or severe diseases with or without fever)~ 7. Axillary temperature\> 37.0 ℃

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Group I-EV71 vaccine and EPI vaccines (Type: EXPERIMENTAL): Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
- Group II-EPI vaccine only (Type: ACTIVE_COMPARATOR): Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
- Group III-EV71 vaccine only (Type: ACTIVE_COMPARATOR): EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete